Nobel Biocare reports positive business trends in 2013

Nobel Biocare has highlighted some of the positive underlying trends driving long-term growth in its financial report for the 2013 business year.

The dental products manufacturer generated revenue of 566.8 billion euros (466.97 billion pounds) during the 12-month period, with 149.6 billion coming in the fourth quarter. For the full year, this represented a year-on-year increase of 2.2 percent on a constant exchange rate basis.

It marked a long-awaited return to growth for Nobel Biocare, with the company also outperforming its peers during the year. The enhanced performance of its high-margin core implant systems business is indicative of the success of its long-term strategy.

The firm has also increased its investments in research and development, streamlined its business and improved its margins in the last year, all of which bodes well for the future.

Richard Laube, chief executive officer of Nobel Biocare, said: "The efficiency initiatives are progressing well and we are well positioned to continue gaining market share and improve profitability sustainably."

Nobel Biocare is looking to maintain its momentum in 2013, launching the first in a new line of creos-branded products last month. Further launches are anticipated in the months to come.